<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15796">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00108277</url>
  </required_header>
  <id_info>
    <org_study_id>MHBA-028-04S</org_study_id>
    <nct_id>NCT00108277</nct_id>
  </id_info>
  <brief_title>Respiratory Dysregulation and Breathing Training in Anxious Outpatients</brief_title>
  <official_title>Respiratory Dysregulation and Breathing Training in Anxious Outpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore respiratory dysregulation in anxious outpatients and examine the
      effect of breathing training with biofeedback for those anxious patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In clinic testing and outside the clinic testing, we will assess the prevalence of
      respiratory dysregulation in a sample of 60 non-psychotic, not currently alcohol or drug
      abusing veteran outpatients from our MHC (Mental Hygiene Clinic) who experience episodic
      anxiety but who do not qualify and have never qualified for the diagnosis of PD (panic
      disorder). These patients will be compared to 30 patients who are not clinically anxious. Of
      these 60 anxious patients, 30 will be randomly assigned to a 4-week course of breathing
      training assisted by feedback of end-tidal pCO2 levels as an augmentation of their current
      treatment. They will be compared to 30 who simply will continue with their current treatment
      (TAU). The breathing training group will receive clinical and physiological assessments
      immediately before the treatment period, four weeks after the end of the treatment period,
      and at a 4-month follow-up. The TAU group will be assessed three times at equivalent
      intervals, and if they wish, may undergo breathing training after the third assessment.
      Treatment will take place mainly in the first two years, giving us adequate time for
      follow-up and data analysis. We expect that this therapy will be especially effective for
      treating anxiety in the patients with substantial respiratory dysregulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Episodic Anxiety Scale</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Episodic Anxiety Scale (EAS) is a modification of the Panic Disorder Severity Scale (Shear et al., 1997) that includes 2 additional questions regarding acute anxiety episodes that may not meet full criteria for a panic attack. The EAS consists of 9 questions, each ranging from 0 (none) to 4 (worst possible). The EAS total score is the sum of all 9 items, such that the minimum total score = 0 (no anxiety symptoms) and maximum total score = 36 (worst possible anxiety symptoms).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Raise CO2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raise CO2 - biofeedback-assisted breathing training to raise baseline pCO2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower CO2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lower CO2 - biofeedback-assisted breathing training to lower baseline pCO2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Waitlist - treatment as usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Breathing Training-Raise CO2</intervention_name>
    <description>while breathing 9 breaths per minute, patients are instructed to raise CO2</description>
    <arm_group_label>Raise CO2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Breathing Training- Lower CO2</intervention_name>
    <description>while breathing 9 breaths per minute, patients are instructed to lower CO2</description>
    <arm_group_label>Lower CO2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be rated 2 or more on both Q1 and Q3, but they must not meet the full
             criteria for PD as determined by the Anxiety Disorders Interview Schedule for
             DSM-IV-Lifetime Version (ADIS).

          -  In addition, they must be clinically stable enough that changes in the patients'
             anxiety levels can be attributed to the breathing training rather than to other new
             treatment initiatives during the training and 1-month evaluation periods or to
             spontaneous fluctuations in anxiety levels. Thus, potential participants taking SSRIs
             or other antidepressants, or benzodiazepines have to have been on a stable dose of
             these medicines for at least the previous two months.

        Exclusion Criteria:

          -  Potential participants taking short-acting benzodiazepines such as alprazolam in
             excess of 2.0 mg/day or the equivalent on any day in the past month are excluded,
             because improvement might show up only in terms of reduction of medication dosage and
             not on the evaluation measures planned.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walton Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Palo Alto Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wollburg E, Roth WT, Kim S. Effects of breathing training on voluntary hypo- and hyperventilation in patients with panic disorder and episodic anxiety. Appl Psychophysiol Biofeedback. 2011 Jun;36(2):81-91. doi: 10.1007/s10484-011-9150-5.</citation>
    <PMID>21373936</PMID>
  </results_reference>
  <results_reference>
    <citation>Doberenz S, Roth WT, Wollburg E, Maslowski NI, Kim S. Methodological considerations in ambulatory skin conductance monitoring. Int J Psychophysiol. 2011 May;80(2):87-95. doi: 10.1016/j.ijpsycho.2011.02.002. Epub 2011 Feb 21.</citation>
    <PMID>21320551</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 7, 2015</lastchanged_date>
  <firstreceived_date>April 14, 2005</firstreceived_date>
  <firstreceived_results_date>December 16, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Breathing Training</keyword>
  <keyword>Respiratory Dysregulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from October 2005 to September 2008 from the local VA medical center and surrounding community. Participants were primarily recruited via posted flyers and other public advertisements (e.g., ads in local newspapers).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Raise CO2</title>
          <description>Raise CO2
Breathing Training-Raise CO2: while breathing 9 minutes per minute, patients are instructed to raise CO2</description>
        </group>
        <group group_id="P2">
          <title>Lower CO2</title>
          <description>Lower CO2
Breathing Training- Lower CO2: while breathing 9 minutes per minute, patients are instructed to lower CO2</description>
        </group>
        <group group_id="P3">
          <title>Waitlist</title>
          <description>Waitlist Treatment as Usual</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raise CO2</title>
          <description>Raise CO2
Breathing Training-Raise CO2: while breathing 9 minutes per minute, patients are instructed to raise CO2</description>
        </group>
        <group group_id="B2">
          <title>Lower CO2</title>
          <description>Lower CO2
Breathing Training- Lower CO2: while breathing 9 minutes per minute, patients are instructed to lower CO2</description>
        </group>
        <group group_id="B3">
          <title>Waitlist</title>
          <description>Waitlist
Treatment as usual</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="35"/>
                <measurement group_id="B4" value="92"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="47.3" spread="13.2"/>
                <measurement group_id="B2" value="40.6" spread="12.2"/>
                <measurement group_id="B3" value="49.9" spread="10.9"/>
                <measurement group_id="B4" value="45.9" spread="12.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="25"/>
                <measurement group_id="B4" value="61"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="48"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="18"/>
                <measurement group_id="B4" value="44"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Episodic Anxiety Scale</title>
          <description>Episodic Anxiety Scale (EAS) is a modification of the Panic Disorder Severity Scale (Shear et al., 1997) that includes 2 additional questions regarding acute anxiety episodes that may not meet full criteria for a panic attack. The EAS consists of 9 questions, each ranging from 0 (none) to 4 (worst possible). The EAS total score is the sum of all 9 items, such that the minimum total score = 0 (no anxiety symptoms) and maximum total score = 36 (worst possible anxiety symptoms).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15.5" spread="3.44"/>
                <measurement group_id="B2" value="15.7" spread="4.53"/>
                <measurement group_id="B3" value="16.1" spread="3.23"/>
                <measurement group_id="B4" value="15.8" spread="3.73"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Episodic Anxiety Scale</title>
        <description>Episodic Anxiety Scale (EAS) is a modification of the Panic Disorder Severity Scale (Shear et al., 1997) that includes 2 additional questions regarding acute anxiety episodes that may not meet full criteria for a panic attack. The EAS consists of 9 questions, each ranging from 0 (none) to 4 (worst possible). The EAS total score is the sum of all 9 items, such that the minimum total score = 0 (no anxiety symptoms) and maximum total score = 36 (worst possible anxiety symptoms).</description>
        <time_frame>1 month</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Raise CO2</title>
            <description>Raise CO2
Breathing Training-Raise CO2: while breathing 9 breaths per minute, patients are instructed to raise CO2</description>
          </group>
          <group group_id="O2">
            <title>Lower CO2</title>
            <description>Lower CO2
Breathing Training- Lower CO2: while breathing 9 breaths per minute, patients are instructed to lower CO2</description>
          </group>
          <group group_id="O3">
            <title>Waitlist</title>
            <description>Waitlist Treatment as usual</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Episodic Anxiety Scale</title>
            <description>Episodic Anxiety Scale (EAS) is a modification of the Panic Disorder Severity Scale (Shear et al., 1997) that includes 2 additional questions regarding acute anxiety episodes that may not meet full criteria for a panic attack. The EAS consists of 9 questions, each ranging from 0 (none) to 4 (worst possible). The EAS total score is the sum of all 9 items, such that the minimum total score = 0 (no anxiety symptoms) and maximum total score = 36 (worst possible anxiety symptoms).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.1" spread="2.73"/>
                  <measurement group_id="O2" value="9.0" spread="3.89"/>
                  <measurement group_id="O3" value="14.3" spread="3.67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Raise CO2</title>
          <description>Breathing Training-Raise CO2: while breathing 9 minutes per minute, patients are instructed to raise CO2</description>
        </group>
        <group group_id="E2">
          <title>Lower CO2</title>
          <description>Breathing Training- Lower CO2: while breathing 9 minutes per minute, patients are instructed to lower CO2</description>
        </group>
        <group group_id="E3">
          <title>Waitlist</title>
          <description>Treatment as usual</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Walton T. Roth, M.D.</name_or_title>
      <organization>VA Palo Alto Health Care System / Stanford University School of Medicine</organization>
      <phone>650-493-5000 ext 65243</phone>
      <email>wtroth@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
